Plan of Operation During the year ended Decemb

Plan of Operation

During the year ended December 31, 2015, SpectraScience continued improvements made to the WavSTAT4 in 2013 under its distribution agreement with PENTAX Europe, GmbH (“PENTAX”), for distribution of its products in Europe, the Middle East and Africa. All of the sales of approximately $6,600 for the year ended December 31, 2015 were to PENTAX.

Over the next 12 months, SpectraScience intends to:

· Market and sell the WavSTAT4 Optical Biopsy System colon cancer diagnostic application through PENTAX and other distribution channels in the European Union;

· Conduct country-specific evaluation trials to demonstrate the effectiveness and cost benefit of the WavSTAT4 Optical Biopsy System in each relevant European jurisdiction;

· Coordinate the creation and publication of scientific papers and presentations related to the country-specific evaluation trials to support widespread education and adoption of the WavSTAT4 ;

· Pursue the introduction of the WavSTAT4 colon cancer application in other international markets, in particular China, the Middle East and India;

· Begin meeting with the FDA towards the preparation and submission of a Supplemental PMA filing with the FDA and plan for additional clinical trials to support eventual approval for sale in the United States;

· Begin the design and planning for the next generation of multi-modal fluorescence and broadband spectroscopy systems at our facility in San Diego, California.

· Continue to expand and refine our intellectual property portfolio.

Guess what folks! Here is the plan from a company that never posts gratuitous PR's or BS of any kind.
Courtesy of dragnet